Title: Analysis of hydrocodone compare d  to a cet a mi n o ph e n  and  i bup rofe n  for p o s t -na il
procedure a nalgesia
NCT # : N C T05544734
Versi o n D ate: 08/15/2022
TITLE: An a l ys i s  o f  h y dro c odon e  c o m p are d t o acetam inoph e n a nd ibup r o fe n f o r  po s t-nail
proce du re  a n a lg es i a
IRB P r oto c ol #:  21-10024054
Vers ion D a t e:  08 / 15 / 2022
Princ ip a l In vest ig at or :
Co-In ves tig at or s:Shar i R . Lipner , MD , P hD
1305  Y or k Av enue
New Y or k, N Y 10021
shl90 32 @ med .c ornell . edu
Jona t han  Hwang , BS
420 E 70 t h  St, LH  13D-1
New Y or k, N Y 10021
jkh40 01 @ med .c ornell . edu
Jose  Ri c ardo , MD
653 E 14 t h  St, A p t 4H
New Y or k, N Y 10009
jwr40 01 @ med .c ornell . edu
Parti c ip a ting Si tes:
Weill C o r ne ll D erma t o l og y -  1305  Y or k Av enue , New  Y or k, N Y 10021
Page # 1
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 /1 5 / 2022
Table  o f C on t en ts
CONFIDENTIALITY STATEMENT .........................................................................................5
1. PROTOCOL SUMMARY ....................................................................................................6
1.1      Schema .....................................................................................................................8
1.2      Study Objectives and End Points .............................................................................4
1.2.1      Primary Objectives ....................................................................................................4
1.2.2      Secondary Objectives ...............................................................................................4
1.2.3 E x plor at or y  Obj ect i ves  .............................................................................. ........ 4
1.2.4      Primary Endpoints .....................................................................................................4
1.2.5      Secondary Endpoints ................................................................................................4
2. BACKGROUND .......................................................................................................................... 4
2.1      Disease ...............................................................................................................................4
2.2      Investigational Agent/Device, or Surgical Treatment/Method ..................................4
2.3      Rationale .............................................................................................................................5
2.4       Risk/Benefit Assessment .........................................................................................6
2.4.1      Known Potential Risks ..............................................................................................6
2.4.2      Known Potential Benefits ..................................................................................6
2.4.3      Assessment of Potential Risks and Benefits .....................................................6
3. STUDY DESIGN ......................................................................................................................... 6
3.1      Overall Design ...................................................................................................................6
3.2      Scientific Rationale for Study Design .......................................................................8
3.3      Justification for Dose .............................................................................................12
3.4      End of Study Definition .....................................................................................................9
4. SUBJECT SELECTION ....................................................................................................13
4.1      Study Population ....................................................................................................13
4.2      Inclusion Criteria ....................................................................................................13
4.3      Exclusion Criteria ...................................................................................................13
4.4      Lifestyle Considerations .........................................................................................13
4.5      Screen Failures ..................................................................................................................9
4.6      Strategies for Recruitment and Retention ..............................................................14
5. REGISTRATION PROCEDURES ............................................................................................ 10
5.1      Subject Registration (WCM only) ...........................................................................14
6. STUDY PROCEDURES ...................................................................................................14
6.1      Schedule of Assessments ......................................................................................14
6.1.1      Screening Visit ( -X days before start of treatment ) .........................................14
6.1.2      Treatment Phase ..............................................................................................15
7. STUDY INTERVENTION ..................................................................................................15
7.1      Study Intervention/Device Description ...................................................................15
Page # 2
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 /1 5 / 2022
7.2      Availability ..............................................................................................................15
7.3      Acquisition and Accountability ..............................................................................16
7.4      Formulation, Appearance, Packaging, and Labeling ..............................................16
7.5      Product Storage and Stability .................................................................................16
7.6      Preparation .............................................................................................................16
7.7      Dosing and Administration .....................................................................................16
7.7.1      Dosing Delays/Dose Modifications ..................................................................16
7.8      General Concomitant Medication and Supportive Care Guidelines .......................16
7.9      Duration of Therapy and Criteria for Removal from Study .....................................16
7.10 Duration of Follow Up ..............................................................................................17
7.11 Measures to Minimize Bias: Randomization and Blinding .......................................17
7.12 Study Intervention/Follow-up Compliance ...............................................................17
8. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT
DISCONTINUATION/WITHDRAWAL ...................................................................................17
8.1      Discontinuation of Study Intervention ....................................................................17
8.2      Participant Discontinuation/Withdrawal from the Study ........................................18
8.3      Lost to Follow Up ....................................................................................................18
9. CORRELATIVE/SPECIAL STUDIES ................................................................................19
9.1      L a bor at or y  Corr e l at i ve  S t udi es  ........................................................................ ...... 16
9. 1 . 1       Ti t l e  ±  L a bor at or y  Correl at i ve  S t ud y  #1 ...................................................... ..... 16
9. 1 . 1 . 1  Coll ect ion o f  Sp ec im e n (s) .......................................................................... ...... 16
9. 1 . 1 . 2  H a ndling o f  Sp ec im e n ( s )  ........................................................................... ...... 16
9. 1 . 1 . 3  Shipping o f  Sp ec im e n ( s )  ( i f  m ul t i ce n ter) ................................................... ...... 16
9. 1 . 1 . 4  Si te(s)  P e r f orming Corr e l at i ve  S t ud y  ( i f  m ul t i ce n ter)  ................................. ..... 16
9.2      Sp ec i a l S t udi es..................... ...........................................................................................16
9. 2 . 1       Ti t l e  ±  Sp ec i a l Corr e l at i ve  S t ud y  #1 ........................................................... ...... 16
9. 2 . 1 . 1  A ssess m e n t................... ...........................................................................................16
9. 2 . 1 . 2  Met hod o f  A ssess m e n t .............................................................................. ...... 16
9. 2 . 1 . 3  Timing o f  A ssess m e n t ............................................................................... ...... 16
10. MEASUREMENT OF EFFECT ............................................................................................. 16
10.1 Response Criteria ..............................................................................................................16
10.2 Duration of Response .......................................................................................................16
10.3 Progression-Free Survival ........................................................................................17
10.4 Other Response Parameters .....................................................................................17
11. DATA REPORTING / REGULATORY CONSIDERATIONS .............................................17
11.1 Data Collection ...................................................................................................................17
11.1.1 REDCap ........................................................................................................................17
11.2 Regulatory Considerations .......................................................................................17
11.2.1 Institutional Review Board/Ethics Committee Approval ....................................17
11.2.2 Ethical Conduct of the Study .............................................................................18
11.2.3 Informed Consent .......................................................................................................18
Page # 3
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 /1 5 / 2022
11.2.4 Compliance with Trial Registration and Results Posting Requirements ...........19
11.2.5 Record Retention ........................................................................................................19
12. STATISTICAL CONSIDERATIONS ................................................................................19
12.1 Study Design/Endpoints ...........................................................................................19
12.2 Sample Size/Accrual Rate .........................................................................................23
12.3 Stratification Factors ................................................................................................23
12.4 Analysis of Endpoints ............................................................................................... 23
12.4.1 Analysis of Primary Endpoints ........................................................................23
12.4.2 Analysis of Secondary Endpoints ...................................................................23
12.5 Interim Analysis ........................................................................................................24
12.6 Reporting and Exclusions ........................................................................................24
12.6.1 Evaluation of Toxicity ......................................................................................24
12.6.2 Evaluation of Response ...................................................................................24
13. ADVERSE EVENT REPORTING REQUIREMENTS ........................................................24
13.1 Adverse Event Definition ..........................................................................................24
13.1.1 Investigational Agent or Device Risks (Expected Adverse Events) ................24
13.1.2 Adverse Event Characteristics and Related Attributions ................................25
13.1.3 Recording of Adverse Events ..........................................................................25
13.1.4 Reporting of AE to WCM IRB ...........................................................................25
13.1.5 Reporting Events to Participants .....................................................................25
13.1.6 Events of Special Interest ................................................................................25
13.1.7 Reporting of Pregnancy ...................................................................................25
13.2 Definition of SAE .......................................................................................................25
13.2.1 Reporting of SAE to IRB ..................................................................................26
13.2.2 Reporting of SAE to FDA [For Protocols Where WCMC is the Sponsor-
Investigator] ..................................................................................................................26
13.2.3 Reporting of SAE to Eclipse Medical ...............................................................26
13.3 AE/SAE Follow Up .....................................................................................................26
13.4 Time Period and Frequency for Event Assessment and Follow Up .........................27
14. UNANTICIPATED PROBLEMS INVOLVING RISKS TO SUBJECTS OR OTHERS .........27
14.1 Definition of Unanticipated Problems Involving Risks to Subjects or Others
(UPIRTSO) ........................................................................................................................27
14.1.2 Unanticipated Problem Reporting ...................................................................24
15. DATA AND SAFETY MONITORING PLAN (DSMP) ........................................................24
16. REFERENCES ................................ ........................................................................................ 26
Page # 4
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 /1 5 / 2022
Stateme nt o f  Compli a n ce
The tri a l will be  c arr i ed  ou t i n  a cc ordan c e  wi t h  I n t erna t ional  Con f eren c e  on  Harmoni s a t ion  Good
Clinic a l Pr ac tic e  ( ICH GCP )  and  t he  f ollowing :
‡ Un it ed  St a t e s ( US )  C ode  o f F ederal  Regula t ion s (C F R)  appli c able  t o  c lini c al  st ud ies
(45 CFR P ar t 46 , 21  CFR P ar t 50 , 21  C F R  P ar t 56 , 21  C F R  P ar t 312 , and / or  21  C FR
Part 812)
Natio na l I n stit u t e s o f H ea lt h  ( NI H)- f unded  in v e st iga t or s and  c lini c al  t rial  s i t e  st a ff who  are
respon si b l e  f or  t he  c ondu ct, managemen t, or  o v er s igh t o f N I H- f unded  c lini c al  t rial s h ave
comp l e t ed  H uman  S ub j e cts P r ot e ct ion  and  I CH  G C P T raining .
The p ro t o c o l, i n f ormed  c on s en t f orm( s ) , re c rui t men t ma t erial s, and  all  par t i c ipan t ma terials
will b e  s ubm itt ed  t o  t he  I n stit u ti onal  Re v iew  B oard  ( I R B )  f or  re v iew  and  appro v al .
Approv a l o f bo t h  t he  pro t o c o l and  t he  c on s en t f orm  mu st be  ob t ained  be f ore  an y pa rtici pan t
is enro ll ed . A n y am e ndmen t t o  t he  pro t o c ol  will  require  re v iew  and  appro val by t he  IRB
before  t he  c hange s ar e implemen t ed  t o  t he  st ud y. I n  addi t ion , all  c hange s to the c on se n t
form will be  IRB -appro v ed ; a  de t ermina t ion  will  be  made  regarding  whe t her  a new c on se n t
need s t o  be  ob t a i ned  f rom  par t i c ipan ts who  pro v ided  c on s en t, u s ing  a  pre viously app r o v ed
cons en t f orm .
Confid e nti a li ty  S tate m e n t
This do c u me n t is c on fi den ti a l and  is t o  be  di st ribu t ed  f or  re v iew  onl y t o  in v e st iga t or s, po t en t i al
investi ga t o rs, c on s u lt an ts, st ud y st a ff, and  appli c able  independen t e t hi cs c ommi tt ee s or
institu ti ona l r e vi e w board s. T he  c on t en ts o f t hi s do c umen t s hall  no t be  di sc lo s ed  t o  o t her s without
written  au t h o r iz a ti on  f rom  WC M , un l e ss di sc lo s ure  on  Clini c al T rial s. go v i s f ederall y require d.
List of Abbr ev i at ion s
WCM W e ill C orne ll Medi c ine
PGIA P h ysici an  Gl o b al  I mpro v emen t Sc ore
PGA P h ysici an  Gl o b al  Ass e ss men t
AE A d v er s e  e v en ts
ADE A d v er s e  D e vic e  Eff e ct
SAE S er i ou s A d v e rs e  Ev en t
UADE U nan tici pa t ed  A d v er s e  De v i c e  Eff e ct
Page # 5
Pro t o c o l #  21-10024054
Versi on  D a t e : 06 / 01 / 2022
1. Pr oto c ol Summ a r y
Full Titl e :
Shor t Titl e :
Clini ca l Ph ase:
Princ ip a l In vest ig at or :
Stud y  D es crip t ion :
Sam pl e  Siz e:
Enroll me nt :
Stud y  Popul at ion :
Enroll me nt P e riod :
Stud y  D es ign :
Descr iption o f  Si tes /
Faciliti es  Enrolling
Parti c ip a n ts:
Stud y  Du r a t ion :
Parti c ip a n t  Dur at ion :Analysis o f h y dro c odone  c ompared  t o  a c e t aminophen  and
ibupro f e n f or  po st -nail  pro c edure  analge s ia
Hydro c odone  f or  po st -nail  s urger y analge s ia
Phas e  4
Shar i R. Lipner  MD , P hD
Nail s ur g er y i s a ss o c ia t ed  wi t h  modera t e  t o  s e v ere  po st opera tive
pain. T he  purpo s e  o f t hi s st ud y i s t o  a ss e ss t he  e ff i c a cy and  safety
of rop ivac aine  and  h y dro c odone  f or  po st -nail  pro c edure  analg esia.
N = 20  par t i c ipan ts.
This st u dy will  enroll  20  s ubje cts and  sc reen  up  t o  30
Patien ts 18  y ear s and  older  undergoing  f ingernail  biop s ie s a t the
Weill Co rnell  Medi c ine , Depar t men t o f Derma t olog y, s pe c ial ty nail
clinic.
07/01 / 2022  ± 07 / 01 / 2023
This is a  randomi z ed , open-label  st ud y, a ss e ss ing  t he  e ff i c a cy
and s a f e ty o f: g r oup a:  in t raopera t i v e  ropi v a c aine  0 . 75%  +
lidoca i ne  1%  and  h y dro c odone  5  mg  + a c e t aminophen  325  mg
(ever y 4  hour s f or  2  da ys, st ar t ing  6  hour s a ft er  s urger y )  f or  nail
procedure-a ss o c ia t ed  analge s ia , c ompared  wi t h  g r oup b :
intraopera t i v e  ropi v a c aine  0 . 75%  + lido c aine  1%  and
acetam i nophen  1000  mg  + ibupro f en  400  mg  (e v er y 6  hour s for 6
days, sta r t ing  6  hour s a ft er  s urger y ) . T he  W ong- B a k er  sc ale  0-to-
10 sc a l e  will  be  u s ed  t o  quan t i t a t e  pain  sc ore s prior  t o  s urger y, at
3 time  poin ts during  s urger y, and  po st opera t i v el y (da ys 0-6) .
Subje ct s  will  be  a sk ed  t o  c omple t e  a  dail y log  where  t he y will
record  pain  t wi c e  dail y during  t he  po st opera t i v e  period . A l s o , the
APS- POQ -R  quali ty o f li f e  s ur v e y will  be  c omple t ed  on
postope r a t i v e  da ys 3  and  6 . A n y s ide  e ff e cts will  be  re c orde d
through o u t t he  st ud y period .
Weill Co rnell  Derma t olog y -  1305  Y or k Av enue , N Y, N Y 100 21
1 year
6 days
Stud y  Ag e n t /D ev i ce  N a m e
Interve n t ion D esc rip t ion :
Lidoc a i ne  1 % (dura ti on  o f a cti on : 1-2  hour s )  and  ropi v a c aine  0 . 75%  (dura t ion  o f a ction: 8
hours )  are  s hor t -  and  l ong-a cti ng  lo c al  ane st he t i cs, re s pe ct i v el y. A mi x o f t he s e  will  be
used  f or  i n t raopera tiv e / po st opera t i v e  ane st he s ia  in  bo t h  st ud y group s. I n  addi t ion ,
subje cts i n  group a  will re c e iv e : oral  h y dro c odone  5  mg  (modera t e- st reng t h
Page # 6
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
opioi d) / a c e t am i nophen  325  mg  (non-opioid  analge s i c ) , e v er y 4  hour s f or  2  da ys, starting 6
hours a ft er  s urger y. O n  po sto pera t i v e  da y 3 , s ubje cts in  g r oup a  will  s wi tc h  t o  or al
acetam i nophen  1000  mg  and  ib upro f en  400  mg  e v er y 6  hour s, un t il  po st opera t i v e  d ay 6.
Patie n ts i n  group b will re c e iv e : a c e t aminophen  1000  mg  and  ibupro f en  400  mg , e very 6
hours, f or  6  da ys, st ar ti ng  6  hour s a ft er  s urger y. Ropi v a c aine  and  lido c aine  are  F D A-
appro v ed  f or  s urg ic a l ane st he s ia . H y dro c odone , a c e t aminophen , and  ibupro f en  are
FDA-appro v ed  f or  po st opera ti ve  analge s ia .
Primary  Obj ect i ve:
Second ar y Obj ect i ves:
Primary  Endpoin ts:
Second ar y Endpoin ts:The pr i mar y obje ct i v e  o f t hi s st ud y i s t o  de t ermine  t he  e ff i c a c y  and
safety o f h y dro c odone / a c e t aminophen  + a c e t aminophen  and
ibupro f e n vs. a c e t aminophen  + ibupro f en , f or  nail  pro c edure-
asso ci a t ed  pain  managemen t.
The s e c ondar y obje ct i v e  o f t hi s st ud y i s t o  de t ermine  t he  imp act of
hydro c o d one / a c e t aminophen  + a c e t aminophen  and  ibupro f e n vs.
acetam i nophen  + ibupro f en  on  heal t h-rela t ed  quali ty o f li f e
asso ci a t ed  wi t h  pain .
The pr im ar y e ff i c a cy endpoin t will  be  t he  c hange  in  pain  sc ore s
obtai ned  wi t h  t he  W ong- B a k er  0- t o-10  pain  sc ale  be t ween  t h e 2
group s on  po st -opera t i v e  da y 2 .
The s e c ondar y endpoin t will  be  t he  c hange  in  heal t h-rela t ed
quality o f li f e  a ss o c ia t ed  wi t h  pain  ob t ained  wi t h  an  adap t ed
versi on  of t he  APS - POQ -R  be t ween  t he  2  group s on  po st -
opera tive da ys 3  and  6 .
Page # 7
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
1.1 S c he ma
Flow di a g ra m
Screen i ng
Visit: D a y 0At lea st 24  hour s pr i or  t o  da t e  o f pro c edure :
Screen  po t en ti a l pa rt i ci pan ts b y i n cl u si on  and  e xcl u si on  c r it er i a ; ob t a i n  h ist or y, re vi e w o f med ic a ti on s, do c umen t. Si g n c on s en t.
Ropiv a c a i ne  0 . 75 % + li do c a i ne  1 % is adm i n ist ered  t o  bo t h  group s f or  i n t raopera tiv e  ane st he si a
Asse ss pa i n  u sin g  t he  W ong- B a k er  0- t o-10  pa i n  sc a l e , pre- s urger y and  dur i ng  s urger y. Giv e  pa i n  da i r i e s t o  s ub jects.
6 hou rs a ft e r
surge ry
Day 3Group a : h y d r o c odone  5  m g /ac e t am i nophen  325  mg  e v er y 4
hours f or  2  da ys.
Group a : St a rt a c e t a mi nophen  1000  mg  and  i bupro f en  400  mg
every 6  hou rs f o r 4  da ys. C omp l e t e  qua lity o f lif e  s ur v e yGroup b :  st ar t a c e t am i nophen  1000  mg  and  ibupro f en  400  mg ,
every 6  hour s f or  2  d ays.
Group b :  c on ti nue  a c e t am i nophen  1000  mg  and  ibupro f en  400
mg, e v er y 6  hour s f or  4  da ys. C omp l e te quali ty o f li f e  s ur v e y
Day 6
Colle cti on  o f pa i n  da i r i e s. C omp l e t e  qua lity o f lif e  s ur v e y.
1.2 Stud y  Obj ect i ves  a nd End Poin ts
1.2.1 Prim a r y  Obj ect i ves
The pr i mar y ob j e ctiv e  o f t h is st ud y i s t o  de t ermine  t he  e ff i c a cy and  s a f e ty o f
hydro c odone / a c e t am i nophen  + a c e t aminophen  and  ibupro f en  vs. a c e t aminophen  +
ibupro f en , f or  na il pro c edure-a ss o c ia t ed  pain  managemen t.
1.2.2 S ec ond a r y  Obj ect i ve s
The s e c ondar y ob j e ctiv e  o f t h is st ud y i s t o  de t ermine  t he  impa ct o f
hydro c odone / a c e t am i nophen  + a c e t aminophen  and  ibupro f en  vs. a c e t aminophen  +
ibupro f en  on  hea lt h-re l a t ed  qu a li ty o f li f e  a ss o c ia t ed  wi t h  pain .
1.2.4  Prim a r y  Endpoin ts
The pr i mar y e ffic a cy endpo i n t will  be  t he  c hange  in  pain  sc ore s, ob t ained  wi t h  t he  Wong-
Bake r  0- t o-10  pa i n  sc a l e , be tw een  t he  2  group s on  po st opera t i v e  da y 2 .
1.2.5  S ec ond a r y  Endpoin t s
The s e c ondar y endpo i n t will b e t he  c hange  in  s ubje ct repor t ed  heal t h-rela t ed  quali t y  of
life a ss o ci a t ed  wit h  pa i n , ob t a in ed  wi t h  an  adap t ed  v er s ion  o f t he  APS - POQ -R , be t w een
the 2  group s on  po st opera tiv e  da ys 3  and  6 .
Page # 8
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
2. Back g r ound
2.1 Di sease
Nail p roc edure s are  a ss o ci a t ed  wit h  modera t e  t o  s e v ere  po st opera t i v e  pain  t ha t c an  b e
presen t up  t o  one  w ee k po st -op . 1  W hile  ropi v a c aine  ha s been  s hown  t o  be  e ff e ct i v e  f or  pain
managemen t a ft er  na il s urg ic a l pr oc edure s in  t he  immedia t e  po st opera t i v e  (up  t o  48  ho urs
followi n g s urger y ) , st ud i e s a ss e ssi ng  s a f e ty and  e ff i c a cy o f pain  managemen t regimens  ha v e
been  li m it ed . 2  R e s ear c h  on  M oh s mi c rographi c s urger y ha v e  s hown  t ha t t he  c o m b i n ati on  o f
oral a c e t am i nophen  1000  mg  + ibupro f en  400  mg , gi v en  e v er y 4  hour s for up t o  4  dose s
(non-op i o i d  ana l ge sics) i s more  e ff e ct i v e  and  ha s a  lower  ri sk o f s ide  e ff e ct s  than
aceta m inophen  + c ode i ne  (op i o i d  analge s i c )  and  a c e t aminophen  alone , f or  po st opera t i ve
analge si a . 3  H o w e v er , a s oppo s ed  t o  nail  s urgi c al  pro c edure s, Moh s mi c rographi c s urg ery is
only a ss o ci a t ed  wit h  m il d  po st ope r a t i v e  pain  (2 , 1 . 5  ou t o f 10  on  po st opera t i v e  da ys 0- 1,
respe ct i v e ly ) . 4  It is c urren tly un k n o wn  whe t her  t hi s c ombina t ion  i s al s o  s uperior  f or  po st-nail
proced u re  ana l ge si a . Eff e ctiv e  pos ts urgi c al  pain  c on t rol  a ff e cts pa t ien t s a t i sf a ct ion , red uces
morb i d ity, and  i mpro v e s re t urn  t o  dail y a ct i v i t ie s and  t o  wor k. 5  It i s t here f ore  e ss en t ial  to
determin e  op ti ma l pa i n  managem e n t al t erna t i v e s f or  nail  pro c edure-a ss o c ia t ed  pain .
Refer e n ces
1. Ric ardo  JW, Qi u  Y, L i pner  S R . Longi t udinal  periopera t i v e  pain  a ss e ss men t in  nai l
surger y. J ounra l o f t he  A mer ica n  Ac adem y o f Derma t olog y. 2021  No v 26 ;S 0190-
9622(21)02911- X.
2. Di C h i a cc h i o  N, Oc ampo- Ga r z a  J, V illarreal- V illarreal  CD , A n c er- A rellano  J, Nori ega
LF, D i C h i a cc h i o  NG. P o st ±nail  pro c edure  analge s ia : A randomi z ed  c on t rol  pilo t st u dy.
Journa l o f t he  A mer ic an  Ac adem y o f Derma t olog y. 2019  S ep  1 ; 81(3) : 860-2 .
3. Sni e z e k PJ, B rod l and  DG, Z i t elli  JA. A randomi z ed  c on t rolled  t rial  c omparing
acetam i nophen , a c e t am i noph e n  and  ibupro f en , and  a c e t aminophen  and  c odeine  f o r
postopera tiv e  pa i n  re li e f a ft er  M oh s s urger y and  c u t aneou s re c on st ru ct ion . Derma tologic
surger y. 2011  J u l; 37(7) : 1007-13 .
4. Firo z BF, G o l dberg  L H, A rnon  O, Mamela k AJ. A n  anal ys i s o f pain  and  analge s i a after
Mohs m ic rograph ic s urger y. Jo urnal  o f t he  A meri c an  Ac adem y o f Derma t olog y. 20 10 Jul
1;63(1) : 79-86 .
5. Ljungq vist O, Sc o tt M , F ear o n  K C . E nhan c ed  re c o v er y a ft er  s urger y: a  re v iew . JAMA
surger y. 2017  Mar  1 ; 152(3) : 292-8 .
2.2 In v e st ig at ion a l Ag e n t /D ev i c e, o r  Su r gi ca l T reatme n t / Met hod
Lidoc a i ne  1 % (dura ti on  o f a cti on : 1 -2  hour s )  and  ropi v a c aine  0 . 75%  (dura t ion  o f a ct ion : 8
hours) are  s hor t and  l ong-dura ti o n o f a ct ion  lo c al  ane st he t i cs, re s pe ct i v el y. A mi x o f t he se
will be  us ed  i n  group s a  and  b , i n filt ra t ed  wi t h  a  wing  blo ck (appro x ima t el y 4  inje ct ion s in to t he
nail f o l d s and  h y pon yc h i um)  fo r  in t raopera t i v e  ane st he s ia , u s ing  a  30-gauge  needle , with
appro xi ma t e ly 1  m l o f s o l u ti on  i n j e ct ed  in  t o t al . I n  addi t ion , s ubje cts in  group  a  will  re c ei ve:
Page # 9
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
oral h y dro c odone  5  mg  (modera t e- st reng t h  opioid  analge s i c ) / a c e t aminophen  325  mg  ( non-
opioi d  a na l ge sic ) , e v er y 4  hour s fo r  2  da ys (12  do s e s in  t o t al) , st ar t ing  6  hour s a ft er  s u rgery.
On po st opera tiv e  da y 3 , pa ti en ts in group  a  will  s wi tc h  t o  oral  a c e t aminophen  1000  mg  +
ibupr o f en  400  mg  e v er y 6  hour s, un t il  da y 6 . P a t ien ts in  group  b  will  re c ei v e : a c e t amino phen
1000  mg + i bupro f en  400  mg  e v er y 6  hour s, st ar t ing  6  hour s a ft er  s urger y, f or  6  da ys.
Ropiv a c a i ne  and  li do c a i ne  are  FDA -appro v ed  f or  s urgi c al  ane st he s ia .
Hydr o co done / a c e t am i nophen , a cet aminophen  and  ibupro f en  are  F D A -appro v ed  f or
treatm en t o f a c u t e-pa i n  managemen t.
2.3 R a tion a l e
Treatme n t reg i men s f or  na il pro c e d ure-a ss o c ia t ed  po st opera t i v e  pain  are  no t well  st udie d.
While  pa i n  managemen t gu i de li ne s f or  c u t aneou s pro c edure s e x i st, c on s en s u s f or  nail
surgic a l pro c edure s is l a cki ng . R a n domi z ed  c on t rolled  t rial s are  t he  main st a y f or
deve l opmen t o f s a f e  and  e ff e ctiv e  t rea t men ts. T here f ore , t here  i s a  need  f or  randomi z ed
contr o ll ed  st ud i e s ob j e ctiv e ly a ss e ss ing  t he  e ff i c a cy and  s a f e ty o f a v ailable  analge s i c
regim e ns f or  managemen t o f pa i n  a ss o c ia t ed  t o  nail  s urgi c al  pro c edure s. W e  hope  t ha t the
UHV X O WVR I WKHSUHVHQ WVWXG\ZLOO J XLGHQDLOVXU J HRQVW RL PS UR Y H qua lity o f lif e  f o ll o wi ng
nail s urger y.
2.4 Ri sk /B e n ef i t  A ssess m e n t
2.4.1  Known Po te n t i a l Ri s k s
Pain a ss o ci a t ed  wit h  ane st he t i c in f il t ra t ion , digi t al  i sc hemia  or  ne c ro s i s. P o t en t ial  s id e
effects o f op i o i d  ana l ge sic h y d r o c odone  in c lude : nau s ea , v omi t ing , c on st ipa t ion ,
somno l en c e , heada c he , euphoria  and  agi t a t ion . P o t en t ial  s e v ere-ad v er s e  rea ct ion s
include  lif e- t hrea t en i ng  re s p i ra t or y depre ss ion , addi ct ion , abu s e , opioid  wi t hdrawal ,
serot on i n  sy ndrome  ( w hen  u s ed  wi t h  s ero t oninergi c agen ts )  and  adrenal  in s u ff i c ie ncy.
Hydr o c odone  is a  c on t ro ll ed  s ub st an c e  and  c la ss i f ied  a s a  Sc hedule  III drug , indi c a ting
that it ha s med ic a l u s e f u l ne ss, bu t al s o  a  po t en t ial  f or  ph ys i c al  and  p syc hologi c al
dependen cy abu s e . P o t en ti a l ri sks o f a c e t aminophen  u s e  in c lude  sk in  ra s h ,
hyper s en sitivity rea cti on , nephro t o x i c i ty, hepa t o t o x i c i ty, anemia , leu k openia , neu t ropen i a ,
pancyt open i a  and  ga st roin t e st inal  rea ct ion s s u c h  a s nau s ea , st oma c h  pain, l o ss o f
appe tit e . S e v ere  liv er  damage  ma y o cc ur  i f t a k ing  more  t han  4000  mg  in  24  hour s,
comb i n i ng  wit h  o t her  dr u g s c on t aining  a c e t aminophen , or  c on s uming  3  or  m ore a lco ho lic
beverage s da ily. P o t en t ial  ri sks o f ibupro f en  in c lude  ga st ri t i s, ul c era t ion , hemorrhage  or
perfora ti on , nephro t o x i c i ty, sk in  ra s h  and  o t her  h y per s en s i t i v e  rea ct i ons.
2.4.2  Known Po te n t i a l B e ne f i ts
Lidoc a i ne  1 % and  rop iv a c a i ne  0 . 75%  are  F D A -appro v ed  f or  in t raopera t i v e  ane st he sia,
adequa t e ly c on t ro lli ng  pa i n  f or  up  t o  8  hour s f ollowing  s urger y. H y dro c odone ,
acetam i nophen  and  i bupro f en  are  all  F D A -appro v ed  f or  t rea t men t o f a c u t e  pain , an d
may pro vi de  adequa t e  c on t ro l of po st opera t i v e  pain  a ss o c ia t ed  wi t h  nail  s urgi c al
procedure s.
Page # 10
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
2.4.3  A ssess m e n t  o f  Po te n t i a l R i sks  a nd Be n ef i ts
Nail s urg ic a l pro c edure s are  a ss o c ia t ed  wi t h  modera t e  t o  s e v ere  pain . A l t hough  opi oid
and non-op i o i d  ana l ge sics are  a ss o c ia t ed  wi t h  v ariou s s e v ere  s ide  e ff e cts, t he s e  are
fortuna t e ly rare . T here f ore , t he  bene f i t o f t he  a ss e ss ed  in t er v en t ion s in  t he  wa y o f p ain
reducti on  ma y s urpa ss t he  a s so c ia t ed  ri sks.
3. Stud y  De s ign
3.1 O v er a ll D es ign
This is a  si ng l e  c en t er , random iz ed , c on t rolled , open-label  st ud y o f 20  pa t ien ts underg oing
finge r na il or  t oena il b i op si e s. P a tie n ts will  be  c on s en t ed  a t lea st 24  hour s prior  t o  t heir  n ail
proced u re . All o t her  st ud y pro c edure s ou ts ide  o f t he  nail  biop sy c an  be  c ondu ct ed  rem otely.
All su r g ic a l pro c edure s will be  per f ormed  b y prin c ipal  in v e st iga t or  Dr . S hari  Lipner  f ollo wing
standa rdiz ed  pro c edure . A m ix o f ropi v a c aine  0 . 75%  + lido c aine  1%  will  be  u s ed  f or
intraopera tiv e  ane st he si a  f or  a ll p at ien ts. P a t ien ts will  be  randomi z ed  in t o  1  o f 2  groups :
Group a:  O ra l h y dro c odone  5  mg  (modera t e- st reng t h  opioid  analge s i c ) / a c e t aminop hen
325 mg  (non-op i o i d  ana l ge sic), e v er y 4  hour s f or  2  da ys (12  do s e s in  t o t al) , st ar t in g 6
hours a ft er  s urger y. O n  po st o p era t i v e  da y 3 , pa t ien ts in  group  a  will  s wi tc h  t o  oral
acetam i nophen  1000  mg  + i bupro f en  400  mg  e v er y 6  hour s, un t il  da y 6 .
Group b :  P a ti en ts i n  group  b  w ill  re c ei v e : a c e t aminophen  1000  mg  + ibupro f en  40 0 mg
every 6  hour s, st ar ti ng  6  hour s a ft er  s urger y, f or  6  da ys.
The Wo ng- B a k er  0- t o-10  pa i n  sc a l e  will  be  u s ed  t o  quan t i t a t e  pain  sc ore s in  all  par t i c ip ants
prior t o  surger y, i n t raopera tiv e ly a n d  during  po st opera t i v e  da ys 0-6  (on c e  in  t he  morning  and
even i n g ) .
An adap t ed  v er si on  o f t he  A mer ic an  P ain  S o c ie ty P a t ien t O u tc ome  Q ue st ionnaire  f or  n ail
surgic al  pa i n  will be  u s ed  t o  quan t i t a t e  heal t h-rela t ed  quali ty o f li f e  a ss o c ia t ed  wi t h  pain  on
postop e ra tiv e  da ys 3  and  6 .
Adve rs e  Ev en ts and  R epor ti ng
Adve rs e  e v en ts ( AE )  a ss e ss men t w ill  be  ongoing  t hroughou t t he  st ud y. A ll  ad v er s e  e v e nts
shall be  repor t ed  b y t he  cli n ic a l I n v e st iga t or  t o  t he  I R B a s de sc ribed  below .
Adve rs e  D e vic e  Eff e ct ( ADE )
Any si g n, sy mp t om , or  d is ea s e  i n  a  st ud y s ubje ct t ha t o cc ur s during  t he  c our s e  o f a  c lin ical
trial t ha t is de t erm i ned  b y t he  i n v e st iga t or  t o  ha v e  a  c au s al  rela t ion s hip  or  po ss ible  c au sal
relati on s h i p  wit h  t he  de vic e  under  in v e st iga t ion .
Seriou s A d v er s e  Ev en t ( SAE )
Any un tow ard  med ic a l o cc urren c e  in  a  s ubje ct, regardle ss o f whe t her  t he  e v en t i s rela t e d to
the de vic e  t ha t:
a. re s ul ts i n  dea t h ;
Page # 11
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
b. re s ul ts i n  a  lif e- t hrea t en i ng  ill n ess or  injur y;
c. re s u lts i n  a  permanen t i mpa i r m en t o f a  bod y st ru ct ure  or  bod y f un ct ion ;
d. require s i n- s ub j e ct ho s p it a liz a ti on  or  prolonga t ion  o f e x i st ing  ho s pi t ali z a t ion
e. require s a  med ic a l or  s urg ic a l i n t er v en t ion  t ha t wa s ne c e ss ar y t o  pre c lude  permanen t
impa ir men t o f a  bod y f un cti on , or  p re v en t permanen t damage  t o  a  bod y st ru ct ure , ei t he r
situa ti o n s u s pe ct ed  t o  be  due  t o  th e  u s e  o f a  medi c al  produ ct.
f. If e x po s ed  pr i or  t o  c on c ep ti on  or  during  pregnan cy ma y ha v e  re s ul t ed  in  an  ad v er s e
outco me i n  t he  c h il d .
g. D oe s no t fit t he  o t her  ou tc ome s, bu t t he  e v en t ma y jeopardi z e  t he  pa t ien t and  ma y
requir e  m ed ic a l or  s urg ic a l i n t er v en t ion  ( t rea t men t )  t o  pre v en t one  o f t he  o t her  ou tc ome s.
Exam p les i n cl ude  a ll erg ic bron c ho s pa s m  (a  s eriou s problem  wi t h  brea t hing)  requiring
treatm en t i n  an  emergen cy room , s eriou s blood  d ysc ra s ia s (blood  di s order s )  or
seizu r es /c on v u lsi on s t ha t do  no t re s ul t in  ho s pi t ali z a t ion . T he  de v elopmen t o f drug
dependen c e  or  drug  abu s e  w ou l d  al s o  be  e x ample s o f impor t an t medi c al  e v en ts.
Seriou s ad v er s e  e v en ts ( SAEs )  a n d  unan t i c ipa t ed  ad v er s e  de v i c e  e ff e cts (U A D Es )  mus t be
report ed  wit h i n  24  hour s o f k no wle dge  o f t he  e v en t t o  t he  I R B.
Unan tic ipa t ed  A d v er s e  D e vic e  Eff e ct (U A D E )  A n y s eriou s ad v er s e  e ff e ct on  heal t h  and
safety o r  an y lif e- t hrea t en i ng  problem  or  dea t h  c au s ed  b y, or  a ss o c ia t ed  wi t h  a  de v i c e , if that
effect, p rob l em , or  dea t h  w a s no t pre v iou s l y iden t i f ied  in  na t ure , s e v eri ty, or  degree  o f
inciden c e  i n  t he  i n v e sti ga ti ona l p l an  or  appli c a t ion , or  an y o t her  unan t i c ipa t ed  s eriou s
probl em  a ss o ci a t ed  wit h  a  de vic e  t ha t rela t e s t o  t he  righ ts, s a f e ty, or  wel f are  o f s ubje cts.
The I n vesti ga t or  s ha ll be  re s pon sib le  f or  de t ermina t ion  o f t he  c au s al  rela t ion s hip  o f all
adve rse e v en ts t o  t he  de vic e  and / or  pro c edure . T he  P rin c ipal  I n v e st iga t or  i s re s pon s ibl e for
monit o ri ng  t he  s a f e ty o f t he  s ub j ec ts enrolled .
Any s e ri ou s ad v er s e  e v en ts will b e re v iewed  and  anal yz ed  b y t he  P rin c ipal  I n v e st iga t or  as
VRR Q DVWKHHYH Q WR FFXUVDQGZLOOEHGRFXPHQWHGLQWK H VXE MHF W
3.2 S c i e n t i f i c  R at ion a l e  f or S t ud y  Des ign
This is a p il o t, random iz ed , c on t ro ll ed , open-label  st ud y a ss e ss ing  t he  u s e  o f h y dro c od one +
aceta min ophen  and  a c e t am i nophen  + ibupro f en  vs. a c e t aminophen  + ibupro f en  alone  for
pain m anagemen t a ft er  na il s urg ica l  pro c edure s.
3.3 J u s ti f i cat ion f or Do se
The do s age  here i n  i n cl uded  ha s b een  a ss e ss ed  in  pre v iou s st udie s on  analge s i c regi mens
for M oh s m ic rograph ic s urger y. Th ere  are  c urren t l y no  guideline s on  t he  pre f erred  analg esic
regim e n f or  po st -na il s urger y ana l ge s ia .
3.4 End o f  S t ud y  D ef ini t ion
A partici pan t is c on si dered  t o  ha ve c omple t ed  t he  st ud y i f he  or  s he  ha s c omple t ed  all
phas e s o f t he  st ud y. T he  end  o f th e  st ud y i s de f ined  a s c omple t ion  o f t he  la st v i s i t or
proced u re .
Page # 12
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
4. Subj ec t S e l ect ion
4.1 Stud y  Popul at ion
Subje ct s  18  y ear s and  o l der  undergoing  f ingernail  or  t oenail , e xc i s ion  or  s ha v e  biop sy a t
speci a liz ed  na il cli n ic, WC M  D epa rt men t o f Derma t olog y f or  an y diagno s i s.
4.2 In c lu s ion Cri te ri a
1. P a tie n ts undergo i ng  fi ngerna il or  t oenail , e xc i s ion , or  s ha v e  biop sy
2. M u st under st and  and  v o l un t ar ily s ign  an  in f ormed  c on s en t f orm
3. M u st be  ma l e  or  f ema l e  and  aged  18-95  y ear s a t t ime  o f c on s en t
4. M u st be  ab l e  t o  adhere  t o  t he  st ud y v i s i t sc hedule  and  o t her  pro t o c ol  requiremen ts
4.3 E xc lu s ion Cri te ri a
1. S ubje ct is unab l e  t o  pro vi de  w ri tt en  in f ormed  c on s en t f or  an y rea s on .
2. S ubje ct ha s per i phera l v a sc u la r  di s ea s e , ar t erial  in s u ff i c ien cy, peripheral  neuropa t h y
3. S ubje ct is on  As p i r i n , NSAIDs, or  c on s ume s a  c hroni c medi c a t ion  f or  c on t rol  o f an y other
chron ic pa i n .
4. S ubje ct ha s a  h ist or y o f op i o i d  or  al c ohol  u s e  di s order .
5. S ubje ct ha s a  h ist or y o f pep tic ul c er  di s ea s e , ga st ri t i s, c hroni c renal  in s u ff i c ien cy or  a
histor y o f ki dne y d is ea s e , or  ha s underl y ing  li v er  di s ea s e
6. S ubje ct ha s a  h ist or y o f s e v er e c on st ipa t ion .
7. S ubje ct is s en sitiv e  or  a ll erg ic t o  an y o f t he  elemen ts in c luded  in  t hi s st ud y.
8. S ubje ct is unab l e  t o  c omp l e t e  t he  required  pain  dair y.
9. S ubje ct is pregnan t, p l ann i ng  p regnan cy, or  nur s ing .
4.4 Lif e s ty l e  Con s id e r at ion s
During  t h is st ud y, par tici pan ts are  a sk ed  t o :
·A b st a i n  f rom  u si ng  an y o t her  analge s i cs di ff eren t t han  t he  one s herein  in c luded  a s well
as an y o t her  t rea t men t moda lity aiming  t o  impro v e  pain  a ft er  nail  s urger y.
4.5 S cree n F a ilur es
Screen  f a il ure s are  de fi ned  a s par t i c ipan ts who  c on s en t t o  par t i c ipa t e  in  t he  c lini c al  t rial  but
are no t s ub s equen tly random ly a ss igned  t o  t he  st ud y in t er v en t ion  or  en t ered  in  t he  st ud y. A
minim al  s e t o f sc reen  f a il ure  i n f or m a t ion  i s required  t o  en s ure  t ran s paren t repor t ing  o f
screen  f a il ure  par tici pan ts, t o  mee t t he  Con s olida t ed  St andard s o f Repor t ing  T rial s
(CONSORT )  pub lis h i ng  requ i remen ts and  t o  re s pond  t o  querie s f rom  regula t or y au t hor ities.
Minim al  i n f orma ti on  i n cl ude s dem o graph y, sc reen  f ailure  de t ail s, eligibili ty c ri t eria , and  a ny
seriou s ad v er s e  e v en t ( SAE ) .
Indivi dua ls w ho  do  no t mee t t he  cr i t eria  f or  par t i c ipa t ion  in  t hi s t rial  ( sc reen  f ailure s )  be cause
of a m o difi ab l e  f a ct or  ma y be  re sc reened . Re sc reened  par t i c ipan ts s hould  be  a ss igned  the
same  par tici pan t number  a s f or  t he  ini t ial  sc reening .
Page # 13
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
4.6 St rate gi es  f or R ec rui t m e n t  a nd Rete n t ion
Patien ts a tt end i ng  W e il C orne ll M e di c ine , Depar t men t o f Derma t olog y, s pe c iali z ed  nail  clinic
for fingerna il or  t oena il b i op sy. 20  par t i c ipan ts will  be  o ff ered  t o  be  in c luded  in  t he  st udy  and
appro xi ma t e ly 30  pa ti en ts will be  sc reened . A ll  par t i c ipan ts will  be  enrolled  in :
Weill C orne ll D erma t o l og y -  1305  Y or k Av enue , New  Y or k, N Y 10021
In the  pre s en t st ud y, par tici pan ts w ill  no t be  c ompen s a t ed  or  pro v ided  an y in c en t i v e s.
5. Re gi s t r a t ion Pro ce dur es
5.1 Subj ect  R e gi st r at ion ( WC M  onl y)
Subje ct s  will be  reg ist ered  wit h i n  t he  W R G -C T a s per  t he  st andard  opera t ing  pro c edur e for
Subje ct R eg ist ra ti on .
6. Stud y  P r o ce dur es
6.1 S c h e dul e  o f  A ssess m e n ts
Table  1 . S c h e dul e  o f  t ri a l eve n t
Screen i ng Visit: D a y 0 D a y 3 D a y 6
Inform ed  c on s en t X
Dem og r aph ics X
Medic a l h ist o ry X
Physic a l e xam X
Conc u rr en t m ed ic a ti on s X X X X
Adve rs e  e v en t e v a l ua ti on X X X
Ropiv a c a i n e + li do c a i ne  ad mi n istr a ti on X
Hydr o c odo n e / a c e t a mi nophen X X
Aceta mi nophen  + i bup r o f en X X X
Patien t qua lity o f lif e  s u rv e y X X
Effica cy a ss e ssm en t X
6.1.1  S c r ee ning Vi s i t
At the  sc reen i ng  visit, a ll i n cl u s ion  and  e xc lu s ion  c ri t eria  will  be  re v iewed . O b t aining
histor y and  re vi e w o f med ic a ti on s will  t a k e  pla c e .
Page # 14
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
6.1.2  Tr eat m e n t  Ph ase
Subje cts w ho  f u lfill a ll i n cl u si on  and  e xc lu s ion  c ri t eria , and  s ign  in f ormed  c on s en t ar e
eligibl e  t o  enro ll and  beg i n  ba s eline  v i s i t pro c edure s 24  hour s a ft er  s igning  c on s en t. After
this b a s e li ne  visit, a ll o t her  pro c edure s c an  be  c ondu ct ed  remo t el y, in c luding  c olle ction of
pain d i ar i e s, med ic a ti on  h ist or y, and  quali ty o f li f e  s ur v e y.
Nail b i op sy will be  per f ormed  u nder  st andardi z ed  pro c edure  b y prin c ipal  in v e st iga t o r Dr.
Shari L i pner . A m ix o f rop iv a c aine  0 . 75%  + lido c aine  1%  will  be  in f il t ra t ed  f or
intraopera tiv e  ane st he si a .
6 hour s a ft er  na il s urger y:
Patien ts i n  group a:  st ar t oral  h y dro c odone  5  mg  (modera t e- st reng t h  opioid
analge sic ) / a c e t am i nophen  325  mg  (non-opioid  analge s i c ) , e v er y 4  hour s f or  2  days
(12 do s e s i n  t o t a l )
Patien ts i n  group b :  st ar t ac e t aminophen  1000  mg  + ibupro f en  400  mg  e v er y 6
hours f or  2  da ys.
On po st opera tiv e  da y 3 :
Patien ts i n  group a:  switc h  t o  oral  a c e t aminophen  1000  mg  + ibupro f en  400  mg
every 6  hour s, un til po st o p era t i v e  da y 6 .
Patien ts i n  Group b :  c on tin ue  a c e t aminophen  1000  mg  + ibupro f en  400  mg  e very 6
hours, un til po st opera tiv e  d a y 6 .
7. Stud y  In te r ve n t ion
7.1 Stud y  In te r ve n t ion/D ev i ce  De scr ip t ion
Lidoc a i ne  1 % (dura ti on  o f a cti on : 1 -2  hour s )  and  ropi v a c aine  0 . 75%  (dura t ion  o f a ct ion : 8
hours) are  s hor t -  and  l ong-a cti ng  l o c al  ane st he t i cs, re s pe ct i v el y. A mi x o f t he s e  will  be  used
for in tr aopera tiv e / po st opera tiv e  a n e st he s ia  in  bo t h  st ud y group s. I n  addi t ion : s ubje cts in
group a  will re c e iv e : ora l h y dro c o d one  5  mg  (modera t e- st reng t h  opioid) / a c e t aminophe n 325
mg (no n -op i o i d  ana l ge sic ) , e v er y 4  hour s f or  2  da ys, st ar t ing  6  hour s a ft er  s urger y. O n
postop e ra tiv e  da y 3 , s ub j e cts i n  group a  will  s wi tc h  t o  oral  a c e t aminophen  1000  mg  a nd
ibupr o f en  400  mg  e v er y 6  hour s, u n t il  po st opera t i v e  da y 6 . P a t ien ts in  g r oup b will  re c e ive:
aceta m inophen  1000  mg  and  i bu p ro f en  400  mg , e v er y 6  hour s, f or  6  da ys, st ar t ing  6  h ours
after s u r ger y. R op iv a c a i ne  and  li d oc aine  are  F D A -appro v ed  f or  s urgi c al  ane st he s ia .
Hydr o co done , a c e t am i nophen , and  ibupro f en  are  F D A -appro v ed  f or  po st opera t i v e  ana l ge si a .
7.2 A v ail a bili ty
Page # 15
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
Ropiv a c a i ne  0 . 75 %, li do c a i ne  1 %, h y dro c odone  5  mg / a c e t aminophen  325  mg ,
aceta m inophen  500  mg  and  i bupr of en  200  mg  are  widel y a v ailable  in  pharma c ie s, and  will
be pu rc ha s ed  b y WC M  Med ici ne , D epar t men t o f Derma t olog y, f or  t he  purpo s e  o f t hi s study.
7.3 A c qui s i t ion a nd A cc oun ta bili ty
Inven t o ry R e c ord s/D e vic e  Log s  ±  T he  in v e st iga t or , or  a  re s pon s ible  par ty de s igna t ed  b y the
investi g at or , will ma i n t a i n  a  c are f u l re c ord  o f t he  in v en t or y and  all  medi c a t ion s here  in c l uded.
7.4 Fo r mul at ion, App ea r a n ce , P acka ging, a nd L a b e ling
Ropiv a c a i ne  h y dro c h l or i de  i n j e cti on  0 . 75%  (150  mg / 20  ml)  gla ss v ial
Lidoc a i ne  h y dro c h l or i de  i n j e cti on  1%  (300  mg / 30  ml)  gla ss v ial
Hydr o co done  b it ar t ra t e  and  a c e t a m inophen  t able ts 5  mg / 325  mg  (12  t able ts will  be
prescrib ed ; Vic od i n)
Aceta mi nophen  500  mg  ea c h  t ab l e t ( Ty lenol  Ext ra  St reng t h)
Ibupr o fe n  200  mg  ea c h  t ab l e t ( A d v il)
7.5 P r odu ct  S t or a g e  a nd S ta bili ty
All m ed ic a ti on s here i n  i n cl uded  wil l  be  st ored  in  a  dr y pla c e  wi t h  t empera t ure  60 °F ± 9 0°F
7.6 P re p a r at ion
A mix o f 0 . 5  m l rop iv a c a i ne  0 . 75 % and  0 . 5  ml  lido c aine  1%  will  be  u s ed  f or
intraopera tiv e / po st opera tiv e  ane st he s ia .
7.7 Do s ing a nd Admini st r at ion
Appr o xi ma t e ly 0 . 5  ±  1  m l o f ane sth e t i c mi x will  be  in f il t ra t ed  f or  in t raopera t i v e / po st opera tive
anest h esi a  wit h  a  wi ng  d i g it a l b l o ck. Do s age  o f all  o t her  medi c a t ion s will  be :
·O ra l h y dro c odone  5  mg  (modera t e- st reng t h  opioid) / a c e t aminophen  325  mg  (non-
opioi d  ana l ge sic ) , e v ery  4  hour s f or  2  da ys, st ar t ing  6  hour s a ft er  s urger y.
·Ac e t am i nophen  1000  mg  and  ibupro f en  400  mg  e v er y 6  hour s, f or  4  or  6  da ys
(depend i ng  on  t he  group)
7.7.1  Do s ing D e l ays /Do se  M odi f i cat ion s
Not app lic ab l e .
7.8 G e n e r a l Con c omi ta n t  Me di c a t ion a nd Suppo rt i ve  Care  Guid e lin es
All con c om it an t med ic a ti on s will be  re c orded  and / or  upda t ed  on  s ubje ct medi c a t ion  c h art
through o u t t he  c our s e  o f t he  st ud y and  s a v ed  in  s ubje ct binder , i f appli c able .
7.9 Du r a t ion o f  Th e r a p y  a nd Cri ter i a  f o r  Rem o va l fr o m  S t ud y
In the  a bs en c e  o f t rea t men t de l a ys due  t o  ad v er s e  e v en t ( s ) , oral  h y dro c odone  5  mg
(mode rat e- st reng t h  op i o i d) / a c e t a m inophen  325  mg  (non-opioid  analge s i c )  will  be  c on sumed
Page # 16
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
for a m a xi mum  o f 2  da ys (e v er y 4  h our s, 12  do s e s in  t o t al) . Ac e t aminophen  1000  mg  an d
ibupr o f e n 400  mg  will be  c on s umed  f or  up  t o  6  da ys (e v er y 6  hour s ) , depending  on  t he
group .
The tr e at men t ma y will be  d isc on tin ued  prior  t o  t he  t ime  s pe c i f ied  abo v e  in  t he  c a s e  o f below
even ts:
·In t er c urren t ill ne ss t ha t pre v en ts f ur t her  admini st ra t ion  o f t rea t men t,
·U na cc ep t ab l e  ad v er s e  ev en t ( s ) ,
·S ub j e ct de ci de s t o  wit hdraw  f rom  t he  st ud y, or
·G enera l or  s pe cific c hange s in  t he  s ubje ct¶ VFRQGLWLRQU s H uQ bjG e c H t UWK H
unacc ep t ab l e  f or  f ur t her  t rea t men t in  t he  judgmen t o f t he  in v e st iga t or .
Study T erm i na ti on  G u i de li ne s: $VXEMHFW ¶ V - up IR in O t O he R s Z t ud y will  end  a ft er  one  o f t h e
followi n g app li e s:
·6 XE M HFW ¶ VYR O X QWDU\ZLWKGUDZDO  ·
S ub j e ct l o st t o  f o ll o w -up
·S ub j e ct dea t h
·C omp l e ti on  o f a ll sc he d uled  st ud y f ollow-up  appoin t men ts
·A n y o t her  ru l e s s pe cific t o  y our  st ud y
7.10 Dur at ion o f  Follow Up
Subje ct s  will be  f o ll o w ed  f or  3  da ys a ft er  t heir  la st do s e . S ubje cts remo v ed  f rom  st ud y for
unacc ep t ab l e  ad v er s e  e v en ts will be  f ollowed  un t il  re s olu t ion  or  st abili z a t ion  o f t he  ad v e rse
even t.
7.11 M eas ur es  t o M inimiz e  Bi as:  Ra ndo m iz at ion a nd B linding
This is a  p il o t open  l abe l st ud y. A randomi z a t ion  t able  will  de t ermine  s ubje ct allo c a t ion  to
each  g r oup  (10  s ub j e cts i n  group a  and  10  s ubje cts in  g r oup b ) .
7.12 Stud y  In te r ve n t ion/Follow - up C o m pli a n ce
During  t he  ba s e li ne  visit ( st andard  o f c are  v i s i t ) , par t i c ipan ts will  be  a sk ed  t o  pro v ide  t he ir
best way o f c on t a ct. All o t her  st ud y pro c edure s will  be  c ondu ct ed  remo t el y. T here  are  no
more  i n-per s on  visits requ i red  f or  t hi s st ud y.
8. Stud y  In te r ve n t ion Di sc on t inu at ion a nd P art i c ip a n t  D i sc on t inu at ion/Wi t hd ra w a l
Partici pan ts ma y wit hdra w v o l un t ar ily f rom  t he  st ud y or  t he  PI ma y di sc on t inue  a  par t i c ipa nt
from t he  st ud y. P ar tici pan ts will be  e xc luded  i f t he y ha v e / de v elop  peripheral  neuropa t h y or  any
other c ond iti on  pre cl ud i ng  t he  a cc ura t e  mea s uremen t o f pain . T he  s ubje ct ge ts pregnan t, i s
plann i ng  p r egnan cy, or  is nur si ng . T h e s ubje ct ha s/ de v elop s peripheral  v a sc ular  di s ea s e  o r
arteri a l i n suffici en cy.
8.1 Di sc on t inu at ion o f  S t ud y  In terve n t ion
Page # 17
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
Discon t inua ti on  f rom  t rea t men t regimen s mean s di sc on t inua t ion  f rom  t he  st ud y. Howe ver, if
a clin ic a lly si gn ific an t fi nd i ng  is i den t i f ied  (in c luding , bu t no t limi t ed  t o  c hange s f rom  ba s e li ne)
after enro ll men t, t he  i n vest iga t or  or  quali f ied  de s ignee  will  de t ermine  i f an y change i n
partici pan t managemen t is needed . A n y new  c lini c all y rele v an t f inding  will  be  repor t e d as an
adve r s e  e v en t ( AE ) .
The da t a  t o  be  c o ll e ct ed  a t t he  ti m e o f st ud y in t er v en t ion  di sc on t inua t ion  will  in c lude  t he
followi n g:
·R ea s on( s )  f or  d isc on ti nua t ion , t a k e  digi t al  pho t ograph s, a ss e ss men t o f
conc om it an t med ic a ti on s.
8.2 P art i c ip a n t  Di sc on t inu at ion/Wi t hd ra w a l fr o m  t h e  S t ud y
Partici pan ts are  f ree  t o  wit hdra w fr om  par t i c ipa t ion  in  t he  st ud y a t an y t ime  upon  reque st.
An in v e sti ga t or  ma y d isc on ti nue  or  wi t hdraw  a  par t i c ipan t f rom  t he  st ud y f or  t he  f ollowin g
reason s:
·P regnan cy
·Si gn ific an t st ud y i n t er v en t ion  non- c omplian c e
·If an y cli n ic a l ad v er s e  ev en t ( AE ) , labora t or y abnormali ty, or  o t her  medi c al
cond iti on  or  sit ua ti on  o cc ur s s u c h  t ha t c on t inued  par t i c ipa t ion  in  t he  st ud y wo uld
not be  i n  t he  be st i n t ere st o f t he  par t i c ipan t
·If t he  par tici pan t mee ts an  e xc lu s ion  c ri t erion  (ei t her  newl y de v eloped  or  no t
previ ou sly re c ogn iz ed)  t ha t pre c lude s f ur t her  st ud y par t i c ipa t ion
·P ar tici pan t unab l e  t o  re c ei v e  st ud y in t er v en t ion( s )
·P ar tici pan t l o st t o  f o ll o w -up  a ft er  s e v eral  a tt emp ts t o  c on t a ct s ubje ct t o  sc hed ule
study visit.
The r e as on  f or  par tici pan t d isc on tin ua t ion  or  wi t hdrawal  f rom  t he  st ud y will  be  re c orde d on
the C as e R epor t F orm  ( CRF ) . S ubje cts who  s ign  t he  in f ormed  c on s en t f orm  and  are
rando miz ed  bu t do  no t re c e iv e  t h e st ud y in t er v en t ion  ma y be  repla c ed . S ubje cts who  sign
the in f o r med  c on s en t f orm , and  ar e randomi z ed  and  re c ei v e  t he  st ud y in t er v en t ion , and
subs eq u en tly wit hdra w, or  are  wit hdrawn  or  di sc on t inued  f rom  t he  st ud y, will  be  repla c e d.
8.3 Lo s t t o Follow Up
A partici pan t will be  c on si dered  l o st t o  f ollow-up  i f he  or  s he  f ail s t o  re t urn  f or  one  or  mo re
schedu l ed  visits and  is unab l e  t o  b e  c on t a ct ed  b y t he  st ud y s i t e  st a ff.
The f o llowi ng  a cti on s mu st be  t a ke n  i f a  par t i c ipan t f ail s t o  re t urn  t o  t he  c lini c f or  a  requ ired
study vi s it:
·T he  sit e  will a tt emp t t o  c on t a ct t he  par t i c ipan t and  re sc hedule  t he  mi ss ed  v is it up
to 7 da ys a ft er  t he  4  w ee ks f rom  t he  pre v iou s v i s i t and  c oun s el  t he  par t i c ipa nt on
the impor t an c e  o f ma i n t aining  t he  a ss igned  v i s i t sc hedule  and  a sc er t ain  i f the
partici pan t wis he s t o  and / or  s hould  c on t inue  in  t he  st ud y.
·B e f ore  a  par tici pan t is deemed  lo st t o  f ollow-up , t he  in v e st iga t or  or  de s igne e will
make  e v er y e ff or t t o  re g ain  c on t a ct wi t h  t he  par t i c ipan t (where  po ss ible , 3
telephone  c a lls and  if po ss ible , 1  email) . T he s e  c on t a ct a tt emp ts s hould  be
GRFXPH Q WH GLQWKHSDUWLFLSDQW ¶ VPHGLFDOUHFRUG RU VWXG\I L
Page # 18
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
·S hou l d  t he  par tici pan t con t inue  t o  be  unrea c hable , he  or  s he  will  be  c on s ide red
to ha v e  wit hdra w n  f ro m t he  st ud y wi t h  a  primar y rea s on  o f lo st t o  f ollow-up .
9. Co rre l a ti ve /Sp ec i a l S t udi es
Not app lic a bl e
10. M eas u re m e n t  o f  E ffect
Pain l e v e ls will be  mea s ured  u si ng  t he  W ong- B a k er  FA C ES 0- t o-10  pain  sc ale :
Healt h -r e l a t ed  qua lity o f lif e  a ss o ci a t e d wi t h  pain  will  be  mea s ured  u s ing  an  adap t ed  v er s io n of
the Am e rica n  P a i n  S o ci e ty P a ti en t O u tc ome  Q ue st ionnaire :
Page # 19
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
10.1 R es pon se  Cri te ri a
Chang e i n  t he  pa i n  l e v e l f rom  ba se line  t o  po st opera t i v e  da ys 2  and  6 .
10.2 Dur at ion o f  R es pon se
Dura ti o n o f o v era ll re s pon s e : T h e dura t ion  o f o v erall  re s pon s e  i s mea s ured  f rom  t he  t i me
meas u re men t c r it er i a  are  me t f or  C R  or  P R  (whi c he v er  i s f ir st re c orded)  un t il  t he  f ir st da te
that r e c urren t or  progre ssiv e  d is ea s e  i s obje ct i v el y do c umen t ed  ( t a k ing  a s re f eren c e  f or
progr e ssiv e  d is ea s e  t he  s ma ll e st mea s uremen ts re c orded  s in c e  t he  t rea t men t st ar t ed) .
Page # 20
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
The du r a ti on  o f o v era ll CR is mea s ured  f rom  t he  t ime  mea s uremen t c ri t eria  are  f ir st m et for
CR un til t he  fi r st da t e  t ha t re c urren t di s ea s e  i s obje ct i v el y do c umen t ed .
Dura ti o n o f st ab l e  d is ea s e : St ab le di s ea s e  i s mea s ured  f rom  t he  st ar t o f t he  t rea t men t until
the crit er i a  f or  progre ssi on  are  me t, t a k ing  a s re f eren c e  t he  s malle st mea s uremen ts
recor ded  si n c e  t he  t rea t men t st ar te d .
10.3 P r ogr ess ion - Fr ee  Sur v i va l
Not A pp lic ab l e .
10.4 Oth e r R es pon se  P a r a m ete r s
Pleas e  see  s e cti on  12 . 5  S ec ond ary  Endpoin ts .
11. D a t a  R e por t ing / R e gul at or y  Con s id erat ion s
11.1 D ata  Coll ect ion
The da t a  c o ll e cti on  p l an  f or  t h is stu d y i s t o  u t ili z e  R E DCap  t o  c ap t ure  all  t rea t men t, t o x i city,
effica cy, and  ad v er s e  e v en t da t a  f or  all  enrolled  s ubje cts.
11.1. 1  REDC a p
REDC ap  ( R e s ear c h  El e ct ron ic Da t a  Cap t ure)  i s a  f ree  da t a  managemen t s o ft ware
syste m  t ha t is f u lly s uppor t ed  by t he  W eill-Cornell  Medi c al  Cen t er  C TS C . It i s a  t oo l for
the c rea ti on  o f c u st om iz ed , s e c ure  da t a  managemen t syst em s t ha t in c lude  W eb-ba sed
data-en t r y f orm s, repor ti ng  t ool s, and  a  f ull  arra y o f s e c uri ty f ea t ure s in c luding  u s er  and
group-ba s ed  pr ivil ege s, au t he nt i c a t ion  u s ing  in st i t u t ion  LD AP syst em , wi t h  a  f ull  au dit
trail o f da t a  man i pu l a ti on  and  ex por t pro c edure s. R E DCap  i s main t ained  on  C TS C-
owned  s er v er s t ha t are  ba ck ed  up  nigh t l y and  s uppor t en c r y p t ed  ( SS L-ba s ed)
conne cti on s. N a ti ona lly, t he  soft ware  i s de v eloped , enhan c ed  and  s uppor t ed  t hroug h a
multi - i n stit u ti ona l c on s or ti um  le d  b y t he  V anderbil t Uni v er s i ty C TSA.
11.2 R e gul at or y  Con s id e r at ion s
11.2. 1  In st i t u t ion a l R ev i e w Bo ar d/E t hi cs  C o mm i ttee  A pp r o va l
As re qu i red  b y l o c a l regu l a ti on s, t he  I n v e st iga t or  will  en s ure  all  legal  a s pe cts are  c o vered,
and appro v a l o f t he  appropr i a t e  regula t or y bodie s ob t ained , be f ore  st ud y ini t ia t ion .
Before  i n iti a ti on  o f t he  st ud y a t ea c h  st ud y c en t er , t he  pro t o c ol , t he  I C F, o t her  written
mate r i a l g iv en  t o  t he  pa ti en ts, and  an y o t her  rele v an t st ud y do c umen t a t ion  w ill be
subm itt ed  t o  t he  appropr i a t e  Et hi cs Commi tt ee . W ri tt en  appro v al  o f t he  st ud y a nd all
relev an t st ud y i n f orma ti on  mu st be  ob t ained  be f ore  t he  st ud y c en t er  c an  be  ini t ia t ed  or the IP
is relea s ed  t o  t he  I n v e sti ga t or . A n y ne c e ss ar y e xt en s ion s or  renewal s o f I R B app roval m u st
be ob t a i ned  f or  c hange s t o  t he  st ud y, s u c h  a s amendmen ts t o  t he  pro t o c ol , t h e ICF,
Page # 21
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
or other  st ud y do c umen t a ti on . T he  wri tt en  appro v al  o f t he  I R B t oge t her  wi t h  t he  ap proved
ICF mu st be  fil ed  i n  t he  st ud y f ile s.
The I n v e sti ga t or  will repor t promp t l y t o  t he  I R B an y new  in f orma t ion  t ha t ma y ad v e rsely
affect t he  s a f e ty o f t he  pa ti en t s  or  t he  c ondu ct o f t he  st ud y. T he  I n v e st iga t or  will  submit
written  s ummar i e s o f t he  st ud y st a t u s t o  t he  I R B a s required . O n  c omple t ion  o f t he  s tudy,
the IRB will be  no tifi ed  t ha t t he  st ud y ha s ended .
All agreed  pro t o c o l amendme nts will  be  c learl y re c orded  on  a  pro t o c ol  amendmen t form
and will be  si gned  and  da t ed  by t he  original  pro t o c ol  appro v ing  s igna t orie s. A ll  pro tocol
amendmen ts will be  s ubm itt ed  t o  t he  rele v an t in st i t u t ional  I R B f or  appro v al  before
implemen t a ti on , a s requ i red  by lo c al  regula t ion s. T he  onl y e xc ep t ion  will  be  wh en the
amendmen t is ne c e ss ar y t o  e li mina t e  an  immedia t e  ha z ard  t o  t he  t rial  par t i c ipan ts. In this
case , t he  ne c e ss ar y a cti on  w ill  be  t a k en  f ir st, wi t h  t he  rele v an t pro t o c ol  amend ment
followi ng  s hor tly t herea ft er .
Once  pro t o c o l amendmen ts o r c on s en t f orm  modi f i c a t ion s are  implemen t ed  a t t h e lead
site, W e ill C orne ll Med ici ne , upda t ed  do c umen ts will  be  pro v ided  t o  par t i c ipa t ing  s i tes, as
applic ab l e . W e ill C orne ll Med i cine  mu st appro v e  all  c on s en t f orm  c hange s prior  t o  local
IRB s ubm issi on .
Relev an t st ud y do c umen t a ti o n will  be  s ubmi tt ed  t o  t he  regula t or y au t hori t ie s of the
partici pa ti ng  c oun t r i e s, a cc ord i ng  t o  lo c al / na t ional  requiremen ts, f or  re v iew  and  app roval
before  t he  beg i nn i ng  o f t he  stu d y. O n  c omple t ion  o f t he  st ud y, t he  regula t or y au t h orities
will b e  no tifi ed  t ha t t he  st ud y ha s ended .
11.2. 2  E t hi ca l Condu ct  o f  t h e  S t ud y
The I n v e sti ga t or s and  a ll par ti e s in v ol v ed  s hould  c ondu ct t hi s st ud y in  adheren c e  to the
ethic a l pr i n ci p l e s ba s ed  on  t he  De c lara t ion  o f Hel s in k i , G C P, I CH  guideline s an d the
applic ab l e  na ti ona l and  l o c a l la w s and  regula t or y requiremen ts.
This st ud y will be  c ondu ct ed  under  a  pro t o c ol  re v iewed  and  appro v ed  b y t he  appl icable
ethics c omm itt ee s and  i n v e sti ga t ion s will  be  under t a k en  b y sc ien t i f i c all y and  me dically
qualifi ed  per s on s, w here  t he  b e ne f i ts o f t he  st ud y are  in  propor t ion  t o  t he  ri sks.
11.2. 3  In f orm e d Con se n t
The i n v e sti ga t or  or  qua lifi ed  d es ignee  mu st ob t ain  do c umen t ed  c on s en t a cc ording t o  ICH-
*&3D QGO RFD O UHJX ODWLRQVDVDSSOLFDEOHIURPH DF KS R W H QW LD O  l eg ally au t hor iz ed
repre s en t a ti ve  prior  t o  par t i c ipa t ing  in  t he  re s ear c h  st ud y. S ubje cts who
agree  t o  par tici pa t e  will si gn  th e  appro v ed  in f ormed  c on s en t f orm  and  will  be  pro v i ded a
copy o f t he  si gned  do c umen t.
The i n iti a l ICF, an y s ub s equen t re v i s ed  wri tt en  I C F and  an y wri tt en  in f orma t ion  pro vided t o
the s ub j e ct mu st appro v ed  by  I R B prior  t o u s e . T he I C F will  adhere  t o  I R B requirem ents,
applic ab l e  l a ws and  regu l a ti on s.
11.2. 4  Compli a n ce  wi t h Tri a l Re gi strat ion a nd Res ul ts  Po st ing Re qui reme n ts
Under  t he  t erm s o f t he  F ood  a n d  Drug A dmini st ra t ion Moderni z a t ion  Act ( F D A M A )  a nd the
Page # 22
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
Food  and  D rug A dm i n ist ra ti on  A mendmen ts Act ( F D AAA ) , t he  S pon s or- I n v e st iga t or  of the
trial is s o l e ly re s pon si b l e  f or  de t ermining  whe t her  t he  t rial  and  i ts re s ul ts are  s ubje ct to the
requi remen ts f or  s ubm issi on  t o  http://www.clinicaltrials.gov . I n f orma t ion  po st ed  will  allow
subje cts t o  i den tify po t en ti a lly appropria t e  t rial s f or  t heir  di s ea s e  c ondi t ion s and  p ursue
partici pa ti on  b y c a lli ng  a  c en t r a l  c on t a ct number  f or  f ur t her  in f orma t ion  on  appropria te trial
locati on s and  t r i a l sit e  c on t a ct in f orma t ion .
11.2. 5  R ec ord R ete n t ion
Esse n ti a l do c umen ts are  t ho s e  do c umen ts t ha t indi v iduall y and  c olle ct i v el y permit
evalua ti on  o f t he  st ud y and  quali ty o f t he  da t a  produ c ed . Aft er  c omple t ion  o f t he  st ud y, all
docu men ts and  da t a  re l a ti ng  t o  t he  st ud y will  be  k ep t in  an  orderl y manner  b y the
Investi ga t or  i n  a  s e c ure  st ud y f ile . Ess en t ial  do c umen ts s hould  be  re t ained  f or  2  years
after t he  fi na l mar k e ti ng  appro v al  in  an  I CH  region  or  f or  a t lea st 2  y ear s s in ce the
disco n ti nua ti on  o f cli n ic a l de ve lopmen t o f t he  IP. I n  addi t ion , all  s ubje cts medi c al  r ecords
and o t her  s our c e  do c umen t a t ion  will  be  k ep t f or  t he  ma x imum  t ime  permi tt ed  by the
hospit a l, i n stit u ti on , or  med ic a l pra ct i c e .
12. St a ti s ti ca l Con s id e r at ion s
12.1 Stud y  D es ign/Endpoin ts
For st ud y de si gn , p l ea s e  s ee  s e cti on  3 . S t ud y  Des ign.
Endpoin ts
The P r i mar y e ffic a cy endpo i n t will  be  t he  c hange  in  pain  sc ore s ob t ained  wi t h  t he  Wong-
Bake r  0- t o-10  pa i n  sc a l e  be tw een  t he  2  group s.
The s e c ondar y endpo i n t will b e t he  c hange  in  heal t h-rela t ed  quali ty o f li f e  a ss o c ia ted
with pa i n  be tw een  t he  2  group s.
12.2 Sampl e  Siz e /A cc ru a l R ate
20 pa ti en ts undergo i ng  fi ngerna il o r  t oenail , e xc i s ion  or  s ha v e  biop sy will  be  in c luded .
12.3 St rat i f i cat ion F act or s
Not ap plic ab l e .
12.4 An a l ys i s  o f  Endpoin ts
12.4. 1  An a l ys i s  o f  Prim a r y  Endpoin ts
Pleas e  s ee  sect ion 12 . 1  S t ud y  d es ign/Endpoin ts
12.4. 2  An a l ys i s  o f  S ec ond a ry Endpoin ts
Pleas e  s ee  sect ion 12 . 1  S t ud y  d es ign/Endpoin ts
Page # 23
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
12.5 In te rim An a l ys i s
Not ap plic ab l e .
12.6 R e por t ing a nd E xc lu s ion s
12.6. 1  E va lu at ion o f  To x i c i ty
All sub j e cts will be  e v a l uab l e  f or  t o x i c i ty f rom  t he  t ime  o f ane st he s ia  in f il t ra t ion , un t il
follow -up  is c omp l e t ed  (3  da ys a ft er  po st opera t i v e  da y 6) .
12.6. 2  E va lu at ion o f  R es pon se
All sub j e cts i n cl uded  i n  t he  st u dy will  be  a ss e ss ed  f or  re s pon s e  t o  t rea t men t i f t he y have
receiv ed  one  t rea t men t.
13. Ad verse  E ve n t  R e por t ing R e qui reme n ts
Adve rs e  e v en t ( AE )  mon it or i ng  and  repor t ing  i s a  rou t ine  par t o f e v er y c lini c al  t rial . T he
investi ga t or  will be  requ i red  t o  pro vi d e appropria t e  in f orma t ion  c on c erning  an y f inding s t ha t
sugge st si gn ific an t ha z ard s, c on t ra i ndi c a t ion s, s ide  e ff e cts, or  pre c au t ion s per t inen t t o  t he  safe
use o f t he  drug  or  de vic e  under  i n v e st iga t ion . S a f e ty will  be  moni t ored  b y e v alua t ion  o f adv erse
even ts r ep o r t ed  b y s ub j e cts or  ob s er ve d  b y in v e st iga t or s or  re s ear c h  st a ff, a s well  a s b y o t h er
investi ga ti o ns s u c h  a s cli n ic a l l abora t or y t e sts, x -ra ys, ele ct ro c ardiograph s, e tc.
13.1 Ad ve r se  E ve n t  D ef ini t ion
An ad v er s e  e v en t (a ls o  re f erre d t o  a s an  ad v er s e  e x perien c e)  c an  be  an y un f a v ora ble
and un i n t ended  si gn  (e . g ., an  abnormal  labora t or y f inding) , sy mp t om , or  di s ea s e
temp ora lly a ss o ci a t ed  wit h  t he  u s e  o f a  drug , and  doe s no t impl y an y judgmen t abou t
caus a lity. A n  ad v er s e  e v en t ca n  ari s e  wi t h  an y u s e  o f t he  drug  (e . g ., o ff -label  u s e , u se in
comb i na ti on  wit h  ano t her  drug ) and  wi t h  an y rou t e  o f admini st ra t ion , f ormula t ion , or  do se,
includ i ng  an  o v erdo s e .
13.1. 1  In vest ig at ion a l Ag e n t  o r  Dev i ce  R i sks  ( E x p ecte d A d verse  E ve n ts)
Pain a ss o ci a t ed  wit h  ane st he t i c in f il t ra t ion , digi t i sc hemia  or  ne c ro s i s. P o t en t ial  s ide
effects o f op i o i d  ana l ge sic h y d r o c odone  in c lude : nau s ea , v omi t ing , c on st ipa t ion ,
somno l en c e , heada c he , euphoria  and  agi t a t ion . P o t en t ial  s e v ere-ad v er s e  rea ct ion s
include  lif e- t hrea t en i ng  re s p i ra t or y depre ss ion , addi ct ion , abu s e , opioid  wi t hdrawal ,
serot on i n  sy ndrome  ( w hen  u s ed  wi t h  s ero t oninergi c agen ts )  and  adrenal  in s u ff i c ien cy.
Hydr o c odone  is a  c on t ro ll ed  s ub st an c e  and  c la ss i f ied  a s a  Sc hedule  III drug , indi c a ting
that it ha s med ic a l u s e f u l ne ss, bu t al s o  a  po t en t ial  f or  ph ys i c al  and  p syc hologi c al
dependen cy abu s e . P o t en ti a l ri sks o f a c e t aminophen  u s e  in c lude  sk in  ra s h ,
hyper s en sitivity rea cti on , nephro t o x i c i ty, hepa t o t o x i c i ty, anemia , leu k openia ,
neutropen i a , pan cyt open i a  an d ga st roin t e st inal  rea ct ion s s u c h  a s nau s ea , st oma c h  pain,
loss o f appe tit e . S e v ere  liv er  damage  ma y o cc ur  i f t a k ing  more  t han  4000  mg  in  24  hour s,
comb i n i ng  wit h  o t her  dr u g s c on t aining  a c e t aminophen , or  c on s uming  3  or  m ore a lco ho lic
beverage s da ily. P o t en t ial  ri sks o f ibupro f en  in c lude  ga st ri t i s, ul c era t ion ,
Page # 24
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
hemorrhage  or  per f ora ti on , nephro t o x i c i ty, sk in  ra s h  and  o t her  h y per s en s i t i v e  rea ct i ons.
13.1. 2  Ad ve r se  E ve n t  Ch a r a c ter i st i cs  a nd Re l ate d Attr ibu t ion s
CTCAE te rm ( AE d esc rip t ion )  a nd g ra d e:  T he  de sc rip t ion s and  grading  sc ale s f o und
in the  re vis ed  NCI C ommon  Te rminolog y Cri t eria  f or  A d v er s e  Ev en ts (C T C AE )  v er sion
5.0 will be  u tiliz ed  f or  AE repo rt ing . A c op y o f t he  C T C AE v er s ion  5 . 0  c an  be
down l oaded  f rom  t he  CTEP w eb  s i t e  (http://ctep.cancer.gov) .
·A tt ribu t ion o f t he  AE:
o D e fi n it e  ±  T he  AE i s c learl y rela t ed  t o  t he  st ud y t rea t men t.
o P robab l e  ±  T he  AE i s li k el y rela t ed  t o  t he  st ud y t rea t men t. o
Possi b l e  ±  T he  AE ma y be  rela t ed  t o  t he  st ud y t rea t men t.
o U n lik e ly ±  T he  AE i s doub tf ull y rela t ed  t o  t he  st ud y t rea t men t.
o U nre l a t ed  ±  T he  AE i s c learl y N OT rela t ed  t o  t he  st ud y t rea t men t.
13.1. 3  R ec ording o f  Ad ve r se  E ve n ts
All ad v er s e  e v en ts will be  re c orded  on  a  s ubje ct s pe c i f i c AE log . T he  AE log  will  be
main t a i ned  b y t he  re s ear c h  st a ff and  k ep t in  t he  s ubje ct¶ VUHVHDUFKFKDUW
13.1. 4  R e por t ing o f  AE t o W CM  I RB
All AEs o cc urr i ng  on  t h is st ud y will  be  repor t ed  t o  t he  I R B a cc ording  t o  t he  I R B poli cy,
which  c an  be  a cc e ss ed  vi a  t he  f ollowing  lin k:
http://researchintegrity.weill.cornell.edu/forms_and_policies/forms/Immediate_Reporting
_Policy.pdf .
13.1. 5  R e por t ing E ve n ts  t o P art i c ip a n ts
Not app lic ab l e .
13.1. 6  E ve n ts  o f  Sp ec i a l In t e rest
Not app lic ab l e
13.1. 7  R e por t ing o f  Pr e gn a n cy
Discon ti nua ti on  o f st ud y i n t er v en t ion , while  c on t inuing  s a f e ty f ollow-up , reque st ing
perm issi on  t o  f o ll o w pregnan t women  t o  pregnan cy ou tc ome .
13.2 D ef ini t ion o f  SAE
SAEs i n cl ude  dea t h , lif e  t hrea t en in g  ad v er s e  e x perien c e s, ho s pi t ali z a t ion  or
prolong ati on  o f ho s p it a liz a ti on , d is abili ty or  in c apa c i t a t ion , o v erdo s e , c ongeni t al
anom a l ie s and  an y o t her  s er i ou s e v en ts t ha t ma y jeopardi z e  t he  s ubje ct or  require
medic al  or  s urg ic a l i n t er v en ti on  t o  pre v en t one  o f t he  ou tc ome s li st ed  in  t hi s
defin iti on .
Page # 25
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
13.2. 1  R e por t ing o f  SAE t o IR B
All SAEs o cc urr i ng  on  t h is st u dy will  be  repor t ed  t o  t he  I R B a cc ording  t o  t he  I R B po licy,
which  c an  be  a cc e ss ed  vi a  t he  f ollowing  lin k:
http://researchintegrity.weill.cornell.edu/forms_and_policies/forms/Immediate_Reporting
_Policy.pdf .
13.2. 2  R e por t ing o f  SAE t o F DA  [ Fo r  P r o t o c ol s  Wh ere  W CMC  i s  t h e  Spon s o r-
Invest ig at or ]
IND app lic a ti on  s pon s or  mu st r epor t an y s u s pe ct ed  ad v er s e  rea ct ion  or  ad v er s e  re action
to stud y t rea t men t t ha t is bo t h  s eriou s and  une x pe ct ed . Une x pe ct ed  f a t al  or  li f e-
threat en i ng  s u s pe ct ed  ad v er se rea ct ion s repre s en t e s pe c iall y impor t an t s a f e ty
informa ti on  and  mu st be  repor t ed  t o  F D A a s s oon  a s po ss ible  bu t no  la t er  t han  7
FDOH QG DU G D \ V I R OO R ZLQ J WKHVSRQVRU ¶ VLQLWLDOUHFHL S W R IWK HL Q  i. dea t h ,
ii. a  lif e- t hrea t en i ng  ad v e rs e  e v en t,
iii. in-pa ti en t ho s p it a liz a ti on  or  prolonga t ion  o f e x i st ing  ho s pi t ali z a t ion ,
iv. a  per sist en t or  si gn ific an t in c apa c i ty or  s ub st an t ial  di s rup t ion  o f t he  abili ty t o
condu ct norma l lif e  f un ct ion s, or
v. a  c ongen it a l anoma ly o r  bir t h  de f e ct
Impo r t an t med ic a l e v en ts t ha t ma y no t re s ul t in  dea t h , be  li f e- t hrea t ening , or  requir e
hospit a liz a ti on  ma y be  c on si d e red  s eriou s when , ba s ed  upon  appropria t e  medi c al
judgmen t, t he y ma y j eopard ize t he  pa t ien t or  re s ear c h  s ubje ct and  ma y require  me dical
or su rg ic a l i n t er v en ti on  t o  pre v en t one  o f t he  ou tc ome s li st ed  a s s eriou s
CDER - onl y  Biologi c  IND s:
Food  and  D rug  A dm i n ist r at ion
Cent er  f or  D rug  Ev a l ua ti o n and  Re s ear c h
Therapeu tic Bi o l og ic P ro d u cts Do c umen t Room
5901- B A mmenda l e  R oa d
Beltsvill e , M D 20705-1266
13.2. 3  R e por t ing o f  SAE t o Kery Fl ex , Pod -A d va n ce , In c
Instit u ti on  will s end  K er yFl e x, P od- A d v an c e , I n c c opie s o f an y and  all  s eriou s ad v e rse
even t repor ts fil ed  wit h  t he  FDA or  o t her  appli c able  regula t or y au t hori t ie s, a s well  a s
copie s o f an y c orre s ponden c e  wi t h  t he  F D A or  o t her  appli c able  regula t or y au t hori t ie s,
regard i ng  an y and  a ll s er i ou s ad v er s e  e v en ts, irre s pe ct i v e  o f a ss o c ia t ion  wi t h  t he  Study
Drug ( s )  i n  t he  c our s e  o f t he  Cli ni c al  T rial , wi t hin  30  bu s ine ss da ys o f s u c h  repor t o r
corre s ponden c e  be i ng  s en t t o  t he  F D A or  o t her  appli c able  regula t or y au t hori t ie s. C opies
shou l d  be  f a x ed  d i re ctly t o  Ecl ip s e  Medi c al  a t (866)-558-0415 .
13.3 AE/SAE Follow Up
All SAE s  and  AEs repor t ed  dur i ng  t hi s st ud y will  be  f ollowed  un t il  re s olu t ion  or  un t il  t he
investi g at or  c on fi rm s t ha t t he  AE/SAE ha s st abili z ed  and  no  more  f ollow-up  i s required . This
requir emen t i nd ic a t e s t ha t f o ll o w -up  ma y be  required  f or  s ome  e v en ts a ft er  t he  s ubje ct
Page # 26
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
discon tin ue s par tici pa ti on  f rom  t he  st ud y.
13.4 Ti me  P e riod a nd Fr e qu e n c y f o r  E ve n t  Assessme n t  a nd Follow U p
The o cc urren c e  o f an  ad v er s e  e ve n t ( AE )  or  s eriou s ad v er s e  e v en t ( SAE )  ma y c ome  t o  the
atten ti o n o f st ud y per s onne l dur i ng  st ud y v i s i ts and  in t er v iew s o f a  st ud y par t i c ipan t
presen ti ng  f or  med ic a l c are , or  up o n  re v iew  b y a  st ud y moni t or .
All AEs i n cl ud i ng  l o c a l and  syst e m i c rea ct ion s no t mee t ing  t he  c ri t eria  f or  SAEs will  be
captu r e d on  t he  appropr i a t e  c a s e  repor t f orm  (CR F ) . I n f orma t ion  t o  be  c olle ct ed  in c lude s
HYH Q W G HVFU L SW L R QWLPHRIRQVHWFOLQLFLDQ ¶ VDVVHV V P H QW R IV H Y HU p r odu ct (a ss e ss ed
only b y t ho s e  wi t h  t he  t raining  and  au t hori ty t o  ma k e  a  diagno s i s ) , a nd
time o f r e s o l u ti on /st ab iliz a ti on  o f th e  e v en t. A ll  AEs o cc urring  while  on  st ud y mu st be
docu me n t ed  appropr i a t e ly regard less o f rela t ion s hip . A ll  AEs will  be  f ollowed  t o  adequa te
resol u ti on .
Any m ed ic a l c ond iti on  t ha t is pre se n t a t t he  t ime  t ha t t he  par t i c ipan t i s sc reened  will  be
consi dered  DVEDVH OLQ HDQ GQRWUHSRUWHGDVDQ$(+RZH YHUL IWK H c ond itio n  de t er i ora t e s a t an y
time during  t he  st ud y, i t will  be  re c orded  a s an  AE.
Chang es i n  t he  s e v er ity o f an  AE will  be  do c umen t ed  t o  allow  an  a ss e ss men t o f t he  du ration
of the  e v en t a t ea c h  l e v e l o f s e v eri ty t o  be  per f ormed . AEs c hara ct eri z ed  a s in t ermi tt en t
requir e  d o c umen t a ti on  o f on s e t a n d  dura t ion  o f ea c h  epi s ode .
Jona t h a n  Hw ang  or  J o s e  Ric ardo  will  re c ord  all  repor t able  e v en ts wi t h  st ar t da t e s o cc ur ring
any time a ft er  i n f ormed  c on s en t is ob t ained  un t il  7  ( f or  non- s eriou s AEs )  or  30  da ys ( f or
SAEs) a ft er  t he  l a st da y o f st ud y par t i c ipa t ion . At ea c h  st ud y v i s i t, t he  in v e st iga t or  will
inquir e  a bou t t he  o cc urren c e  o f AE/SAEs s in c e  t he  la st v i s i t. Ev en ts will  be  f ollowed  f o r
outco me i n f orma ti on  un til re s o l u tio n  or  st abili z a t ion .
14. Un a nti c ip ate d Probl e m s  In v ol v ing R i sks  t o Subj ects  o r  O t h ers
14.1 D ef ini t ion o f  Un a n t i c ip ate d P r obl ems  In v ol v ing R i sks  t o Subj ects  o r  O t h ers
(UPIRTSO )
This de fi n iti on  c ou l d  i n cl ude  an  unan t i c ipa t ed  ad v er s e  de v i c e  e ff e ct, an y s eriou s ad v er se
effect on  hea lt h  or  s a f e ty or  an y life - t hrea t ening  problem  or  dea t h  c au s ed  b y, or  a ss o c ia ted
with, a  de vic e , if t ha t e ff e ct, prob l em , or  dea t h  wa s no t pre v iou s l y iden t i f ied  in  na t ure ,
seve rity, or  degree  o f i n ci den c e  i n  t he  in v e st iga t ional  plan  or  appli c a t ion  (in c luding  a
supp l e m en t ar y p l an  or  app lic a ti on) , or  an y o t her  unan t i c ipa t ed  s eriou s problem  a ss o c ia ted
with a  d e vic e  t ha t re l a t e s t o  t he  r ig h ts, s a f e ty, or  wel f are  o f s ubje cts (21  C F R  812 . 3( s )) .
14.1. 2  Un a n t i c ip ate d Probl em  Re po rt ing
An inv e sti ga t or  s ha ll s ubm it t o  t he  s pon s or  and  t o  t he  re v iewing  I n st i t u t ional  Re v ie w
Boar d  ( IRB )  a  repor t o f an y un a n t i c ipa t ed  ad v er s e  de v i c e  e ff e ct o cc urring  during  a n
investi ga ti on  a s s oon  a s po ssib le , bu t in  no  e v en t la t er  t han  10  wor k ing  da ys a ft er  t h e
investi ga t or  fi r st l earn s o f t he  e ff e ct (21  C F R  812 . 150(a)(1)) , A s pon s or  who  c ondu cts an
evalua ti on  o f an  unan tici pa t ed  ad v er s e  de v i c e  e ff e ct under  812 . 46(b)  s hall  repor t t h e
Page # 27
Pro t o c o l #  21-10024054
Versi on  D a t e : 08 / 15 / 2022
results o f s u c h  e v a l ua ti on  t o  th e  F ood  and  Drug  A dmini st ra t ion  ( F D A )  and  t o  all
revie wi ng  IRB's and  par tici pa ti ng  in v e st iga t or s wi t hin  10  wor k ing  da ys a ft er  t he  s po nsor
first re c e iv e s no tic e  o f t he  e ff ec t. T herea ft er  t he  s pon s or  s hall  s ubmi t s u c h  addi t ion al
repor ts c on c ern i ng  t he  e ff e ct as F D A reque sts (21  C F R  812 . 150(b)(1)) .
15. D a t a  a nd S afety  M oni t oring Pl a n (D S M P )
In this s e ctio n , p l ea s e  i n cl ude  a w r itt en plan o f t he  mea s ure s t ha t will  be  t a k en  t o en s ure  t he  safety o f
clinic a l res ear c h  s ub j e cts and  pro tect t he  v alidi ty and  in t egri ty o f re s ear c h  da t a . T he  f oll owing
questi on s s hou l d  be  addre ss ed  a s a  p ar t o f t he  D S M P and  mu st be  in c orpora t ed  in t o  y our  WCM
eIRB app lic a ti on :
·Incl ude  a  de sc r i p ti on  o f t he  propo s ed  moni t oring  en t i ty (i . e . W CM  D S M B, I ndep endent
Medic a l Mon it or)  and  ra ti onale  f or  c hoo s ing  t he  s pe c i f ied  moni t oring  en t i ty. If you are
using  an  i ndependen t medi c al  moni t or  or  st ud y moni t oring  c ommi tt ee / group , p lease
specify t he i r  qua lific a ti on s.
·De sc r i be  t he  da t a / e v en ts t ha t will  be  c ap t ured  and  s ubmi tt ed  t o  t he  moni t oring  entity.
Specify w ha t da t a  will be  co lle ct ed  during  t he  c our s e  o f t he  st ud y t o  a ss e ss bo t h  safety
and e ffic a cy.
·De sc r i be  w ha t ad v er s e  e v e nts ma y c au s e  t he  s ubje ct t o  t ermina t e  pro t o c ol  t rea tment.
Specific a lly, de sc r i be  t rea tm en t st opping  rule s f or  an  indi v idual  s ubje ct.
·Ho w will ad v er s e  e v en ts a n d  unan t i c ipa t ed  problem s be  repor t ed  t o  t he  mon itoring
entity and  wit h  w ha t f reque ncy ?
·Ho w o ft en  will t he  mon it or in g  en t i ty re v iew  da t a / e v en ts (i . e . annuall y, s emi-an nually,
etc.)
·De sc r i be  t he  c omp l e t e  st ud y st opping  rule s ( c ri t eria  f or  st ud y s u s pen s ion  and  po tential
study t erm i na ti on)  st a tistic al  c on s idera t ion s. If t here  are  no  de f ined  st opping  rules,
pleas e  pro vi de  a  ra ti ona l e . A l s o , st a t e  an y s pe c i f i c t rigger s f or  a ct ion .
·All do s e  e sc a l a ti on  t r i a ls ar e required  t o  de f ine  do s e  limi t ing  t o x i c i t ie s, rule s f or
esca l a ti on  o f do s e , and  c r it eria  f or  st opping  t he  t rial  and  de f ining  t he  Ma x imum
Tolera t ed  D o s e .
·Ho w will t he  mon it or i ng  H Q W LW\ ¶ VFRPPHQWVUHYLHZEHGLVVHP L Q D W H G" HJ
theIRB a t t he ti me o f c on ti n u ing re v iew and s ubmi tt ed t o par t i c ipa t ing s i t e s upon r eceipt
of revi e w c ommen ts. )
Page # 28